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1. Introduction 
Although the effective immune response against Mycobacterium tuberculosis (M. tuberculosis, 
Mtb) is primarily due to cell-mediated immunity, the mechanisms by which T cells 
participate in the control of infection are still not completely understood. The importance of 
CD8+ T cells in the immune response to tuberculosis has been recognized by many 
researchers [1]. Experimental evidence from the murine model indicated that CD8+ T cells 
could be important to the control of Mycobacterium tuberculosis infection in vivo [2-5]. The 
isolation of M. tuberculosis-specific CD8+ T cells from infected mice and human clearly 
showed that this subset could be induced during infection [6-8]. Reports on epitope-specific 
M. tuberculosis reactive CD8+ T cells, which are present at very high frequencies in the 
peripheral blood of PPD positive individuals and patients with active tuberculosis, support 
the importance of CD8+ T cells to the immunity of M. tuberculosis and emphasize that the 
CD8+ T cell subset should be considered to the design of new anti-tuberculosis vaccines [9, 
10]. CD8+ T cells may contribute to the control of M. tuberculosis infection through four 
mechanisms: (1) Cytokine release, such as IFN-γ and TNF-α; (2) Cytotoxicity via granule-
dependent exocytosis pathway; (3) Cytotoxicity mediated through Fas/Fas ligand 
interaction; (4) Direct microbicidal activity. 
The pathogen’s antigens are processed by antigen presenting cells (APCs) and digested 
into short peptides. Consequently, these non-self peptides are presented to the surface of 
the infected cells or APCs through the loading of the major histocompatibility complex 
(MHC) or called human leukocyte antigen (HLA) in human. These peptide/MHC 
complexes are recognized by specific T-cells that perform immune responses, such as 
cytotoxicity (in the case of class I MHC). These peptides which act as the markers of the 
pathogens are called T cell epitopes [11]. The identification of novel cytotoxic T 
lymphocyte (CTL) epitopes is important to the analysis of the involvement of CD8+ T cells 
in M. tuberculosis infection as well as the anti-Mtb vaccine development. However, only a 
small number of MHC-I-restricted CTL epitopes have been identified within a few of M. 
tuberculosis proteins. The step to develop epitope-based vaccines include: (1) antigen 
selection; (2) epitope prediction; (3) epitope identification; (4) vaccine prototype 
engineering; (5) immunization and challenge studies. In this chapter we mainly focused 
on the strategy to identify CD8+ T cell epitopes against Mycobacterium tuberculosis. It 
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includes: selection of the antigens; Prediction the CD8+ T cell epitopes; Synthesis and 
modification of the epitopes; Identification of epitopes by in vitro and in vivo assays; 
Development of CD8+ T cell epitope-based vaccines. 
2. Selection of antigens from Mycobacterium tuberculosis 
An essential step towards the development of novel vaccines against Mtb is gaining more 
information on the antigenic architecture of Mycobacterium tuberculosis to identify T-cell 
epitopes responsible for eliciting protective immune responses. Determination of the 
complete genome sequence of Mycobacterium tuberculosis facilitated this step considerably. 
The H37Rv strain of Mycobacterium tuberculosis has been found extensive, worldwide 
application in biomedical research because it has retained full virulence in animal models. 
Cole et al reported the complete genome sequence of H37Rv in 1998 [12]. This progress in 
genomics makes it possible that we can find corresponding protein sequences through 
submitting to publicly accessible sequence databases such as GenBank and TB database 
[13]. 
The Mtb genome contains about 4,203 open reading frames, nearly half of which are 
categorized as ‘hypothetical proteins’ with unknown function. Although secreted proteins 
are generally associated with protective immune responses, no proteins or protein families 
have yet been shown to fully protect against the active Mtb infection. Screening each protein 
from these 4,023 open reading frames by using human serum and gel electrophoresis would 
be time-consuming and costly method of identifying new vaccine candidates. Bioinformatics 
tools provide more practical means to rapidly identify potential epitopes and antigens for 
Mtb vaccines development. A range of approaches have been utilized to select proteins for 
analysis prior to epitope mapping. For example, whole genome analysis can be performed 
in order to identify candidate vaccine components, or alternatively, bioinformatics tools that 
select proteins according to their secretion characteristics can be used to narrow the number 
of proteins evaluated in the next step [14-16]. Frieder et al used pepmixes created by Micro-
Scale SPOTTM to map T cell epitopes in 389 proteins of Mycobacterium tuberculosis [17]. These 
proteins are sorted by their known or likely known function such as PPE/PE, cell wall, cell 
processes, virulence, detoxification, and adaptation. Some CD8+ T cell epitopes identified by 
researchers were listed in Table 1. 
So far, antigens in Mycobacterium tuberculosis from which CD8+ T cell epitopes were 
identified are mainly focused on secretory proteins, lipoproteins, such as Ag85-complex, 
ESAT-6, CFP10, 16kDa protein, 19kDa lipoprotein and so on. But there are few studies 
focused on the membrane proteins like the drug efflux pumps which play important role in 
the drug-resistant of Mycobacterium tuberculosis. Researchers in our lab tried to identify novel 
CD8+ T cell epitopes from these antigens and found several novel CD8+ T cell epitopes 
which could elicit potent immune responses both in vitro and in vivo [32]. 
3. Prediction of the CD8
+
 T cell epitopes 
The lack of simple methods to identify relevant T-cell epitopes, the high mutation rate of 
many pathogens, and restriction of T-cell response to epitopes due to human lymphocyte  
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Protein 
name 
Gene description  Amino 
acid 
position 
HLA 
allele 
Frequency References 
Ag85A mycolyltransferases  48-56 
 
242-250 
HLA-A2 
 
HLA-A2  
1/20,693PBMC
s (Elispot) 
1/3,300 
PBMCs 
(tetramer) 
1/23,779 
PBMCs 
(Elispot) 
1/3,750 
PBMCs 
(tetramer) 
 
[18] 
Ag85B mycolyltransferases  143–152 
199–207 
264–272 
HLA-A2 
HLA-A2 
HLA-B35
ND 
Undetectable 
(tetramer) 
ND 
[19, 20]  
Ag85C mycolyltransferases   204–212 HLA-B35  1/13,700–
1/22,200 
PBMCs 
[20] 
ESAT-6 Early secretory antigen target  69–76  
 82–90 
 21–29 
HLA-B53
HLA-A2 
HLA-
A6802 
1/700 CD8+ 
1/2,500 
PBMCs 
1/2,100 CD8+ 
[21, 22] 
CFP10 10kDa culture filtrate antigen 2–9  
2–12 
3–11 
75–83 
2–11 
49–58 
85–94 
71–79 
76–85 
HLA-
B4501 
HLA-
B4501 
HLA-
B0801 
HLA-
B1502 
HLA-B44
HLA-B44
HLA-
B3514 
HLA-B14
HLA-
B3514 
 
1/101 CD8+ 
1/125 CD8+ 
1/645 CD8+ 
1/145 CD8+  
1/700 CD8+ 
1/7,000 CD8+ 
1/2,100 CD8+ 
1/438–1/1,602 
PBMCs  
1/437–1/2,427 
PBMCs  
[11, 23, 24]  
CFP21 cutinase precursor 134-142 HLA-A2 
 
3/5000-
1/10000 
PBMCs 
((Elispot))  
[25] 
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Protein 
name 
Gene description  Amino 
acid 
position 
HLA 
allele 
Frequency References 
Mtb8.4 low molecular weight T-cell 
antigen  
5–15 
32–40 
HLA-
B1501 
HLA-
B3514 
1/10,416 CD8+  
1/1,190 CD8+  
[23] 
Mtb9.8 Hypothetical protein 
 
3–11 
53–61 
HLA-
A0201 
HLA-
B0801 
 <1/25,000 
CD8+ 
 1/2,840 CD8+ 
[23] 
Mtb39 PPE family protein 
 
144–153 
346–355 
HLA-B44
HLA-B44
ND 
ND 
[26] 
16kDa 
protein 
heat shock protein  21–29 
120–128 
HLA-A2 
HLA-A2 
1/1,000 CD8+ 
1/800 CD8+ 
[19] 
19kDa 
lipoprotein 
19 kDa lipoprotein antigen 
precursor  
88–97 HLA-A2 ND [27] 
38kDa 
protein 
periplasmic phosphate-
binding lipoprotein  
 
8–17 HLA-
A0201 
1/331 CD8+  [28] 
Hsp65  chaperonin 369–377 HLA-A2 ND [29] 
Rv0341 isoniazid inductible gene 
protein 
33–42 
33–44  
33–45 
HLA-A2 
HLA-A2 
HLA-A2 
ND 
ND 
ND 
[30] 
Rv2903c signal peptidase 201–209 HLA-B35 Undetectable [31] 
Rv1410c aminoglycosides/tetracycline
-transport integral membrane 
protein  
 
510-518 HLA-
A0201 
 
3/2500 PBMCs  [32] 
GlnA1  glutamine synthetase  308–316 HLA-A2 ND [33]  
SodA  superoxide dismutase 160–168 HLA-A2 ND  [32]  
AlaDH  delta-aminolevulinic acid 
dehydratase 
 
160–169 HLA-A2 ND [32] 
Hemolysin  cytotoxin/hemolysin 73–82  HLA-
A0201 
 
1/353 CD8+ [28] 
Table 1. CD8+ T cell epitopes identified in Mycobacterium tuberculosis  
antigen (HLA) polymorphism have significantly hindered the development of cytotoxic  
T-lymphocyte (CTL) epitope-based or epitope-driven vaccines. As the development of 
bioinformatics, computer-driven algorithms methods for predicting CD8+ T cell epitopes are 
used as important tools to the vaccine design. These tools offer a significant advantage over 
other methods of epitope selection because high-throughput screening can be performed in 
silico, followed by consequent immunological experiments in vitro and in vivo [34]. 
Traditionally, the identification of T cell epitopes required the synthesis of overlapping 
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peptides that spanned the entire length of a protein, followed by experimental assays for 
each peptide, such as in vitro intracellular cytokine staining, to determine the T cell 
activation. This method is economically viable only for single protein or pathogen that 
consists of fewer proteins. As a result, alternative computational approaches have been 
developed for the prediction of T cell epitopes, which have significantly decreased the 
experimental burden that is associated with epitope identification. Computer-driven 
algorithms are now routinely employed to sort through protein sequences for linear strings 
of amino acids that confirm to previously established patterns known to be associated with 
the binding to antigen presenting molecules (such as MHC) and stimulation of T cells. These 
peptide strings, once proven to stimulate T cells in vitro or in vivo, are considered as T cell 
epitopes. 
A lot of computational algorithms have been developed to predict CTL epitopes in pathogen 
protein sequences (some of these are listed in Table 2). In reality, using only one 
computational algorithm to predict CTL epitopes may lead to large number of false 
positives and false negatives. Later and more comprehensive validations using data from 
several different prediction softwares are accurate and of high value in reducing the cost for 
epitope identification. Researchers in our lab used several prediction servers and identified 
novel CTL epitopes successfully [25, 32]. 
4. Synthesis and modification of the epitopes 
Solid phase peptide synthesis (SPPS) offers important advantages over the synthesis in 
solution, in which coupling reactions can be carried out more rapidly and nearly to 
completion using an excess of the activated amino acid derivative, which can be removed at 
the end of the reaction by simple washing operations. The introduction of Fmoc protecting 
group into SPPS by Carpino in 1970 allowed the entire process of SPPS to be carried out 
under milder reactive conditions [35]. As a result of this chemical progress, nowadays the 
synthesis of many peptides can be smoothly accomplished by manual or automate-assisted 
SPPS and even longer proteins can be synthesized by coupling protected segments or more 
efficiently by chemical ligation with unprotected peptide segments [36]. 
The immunogenicity of the native epitope is often weak. Substitutions at main anchor 
positions to increase the complementarity between the peptide and HLA binding cleft 
constitute a common procedure to improve the binding capacity and immunogenicity of the 
native epitope. In 1993, Ruppert et al determined that the ‘canonical’ HLA-A2.1 motif could 
be defined as leucine (L) or methione (M) at position 2 (P2) and leucine (L), valine (V), or 
isoleucine (I) at position 9 (P9) [37]. In 2000, Tourdot et al demonstrated that residue 
tyrosine (Y) at position 1 (P1) could enhance the affinity of epitope to HLA-I molecule [38]. 
These results suggested that an altered peptide ligand (APL) might be used to exploit a 
latent capacity of the T cell repertoire to respond more effectively to the native epitope. We 
also used this strategy to modify the related positions and found the binding capacity and 
immunogenicity of some epitopes improved [25, 32]. The second strategy is to modify the 
amino acids with a side chain protruding out of the peptide binding cleft of the HLA 
molecule, because these amino acids may participate in T cell receptor (TCR) recognition. If 
they are substituted by amino acids with other properties, a mutated epitope may bind more 
efficiently to TCR or elicit a more diverse TCR reservoir [39, 40]. 
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ID server Abbreviation Prediction algorithm 
1 BIMAS  BIMAS  Matrixa 
2 HLA Ligand HLA_LI Matrixa 
3 IEDB (ANN)  IEDB_ANN ANNb 
4 IEDB (ARB) IEDB_ARB  Matrixa 
5 IEDB (SMM) IEDB_SMM Matrixa 
6 MAPPP (Bimas)  MAPPP_B  Matrixa 
7 MAPPP(SYFPEITHI) MAPPP_S Matrixa 
8 MHC Binder Prediction MHC_BP Matrixa 
9 MHC-BPS MHC-BPS SVMc  
10 MHC-I (Multiple matrix) MHCI_MM  Structure-based model 
11 MHC-I (Single matrix)  MHCI_SM Structure-based model 
12 MHCPred (Interactions) MHCP_I  Partial least square 
13 MHCPred (Amino Acids) MHCP_AA Partial least square 
14 MULTIPRED (ANN)  MULTI_ANN ANNb 
15 MULTIPRED (HMM)  MULTI_HMM HMMd 
16 MULTIPRED (SVM) MULTI_SVM SVMc 
17 NetMHC (ANN)  NETM_ANN ANNb 
18 NetMHC (Weight Matrix) NETM_WM Matrixa 
19 nHLAPred (ANNPred) NHP_ANN ANNb 
20 nHLAPred (ComPred)  NHP_CP  ANNb and Matrixa  
21 PepDist   PEPDIST distance function 
22 PeptideCheck (Matrix) PEPC_M Matrixa 
23 Predep PREDEP Structure-based model  
24 ProPred1  PROPRED Matrixa 
25 Rankpep RANKPEP Matrixa 
26 SMM  SMM  Matrixa 
27 SVMHC (MHCPEP) SVMHC_M SVMc 
28 SVMHC (SYFPEITHI)  SVMHC_S SVMc 
29 SVRMHC SVRMHC SVMc 
30 SYFPEITHI  SYFPEITHI  Matrixa 
a: binding  matrices  
b: artificial  neural  networks  
c: support vector machines  
d: hidden  Markov  models 
Table 2. Some epitope prediction servers 
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5. Identification of epitopes by in vitro and in vivo assays 
The immunogenicity of epitopes predicted through appropriate prediction softwares should 
be identified by a series of in vitro and in vivo assays. Only epitopes which are proven to 
stimulate T cells in vitro or in vivo can be used as potential subunit components for the 
design of vaccines against tuberculosis. Because there are various techniques to identify 
specific T-cell epitopes, the question arises about how to select and combine these 
techniques to screen peptides more efficiently and rapidly.  
According to the processing and presenting progress of T cell epitopes and their ability to 
specifically stimulate T cells in an MHC allele-restricted manner. The pathway of MHC-I 
eptiope presentation has been exhibited and the process comprise three main steps: firstly, 
endogenous proteins are digested into short peptides by proteasomes; secondly, special 
epitopes are selected to load onto MHC-I molecule within the endoplasmic reticulum; 
finally, the peptide/MHC complexes are transferred to cell surface and to stimulate specific 
T-cell receptors on T cells. Therefore, there are three essential elements for a random peptide 
to be considered as MHC-I restricted T cell epitope. First, the peptide must be naturally 
processed into an optimal length via a proteasome dependent pathway. Second, the peptide 
should have the affinity to bind to the corresponding MHC-I molecule. Finally, and perhaps 
the most important, the peptide must have the ability to induce a T-cell-specific response 
after its presentation on an MHC-I molecule [11]. Thus, the techniques to evaluate the three 
features of a given peptide can be classified into three corresponding types: MHC-binding 
assay; T cell specific antigenicity assay; Verification of the natural processing of the peptide. 
5.1 MHC binding assay 
Various methods have been developed to evaluate the binding affinity of peptides to MHC-I 
molecule. Standard peptide binding inhibition assay is a common method used to 
quantitatively measure the binding affinity of the target peptides [41]. The MHC-I 
transfected cell line binding assay was utilized in many labs for its simplicity, repeatability 
and quantifiability for determining peptide and MHC-binding affinities [25, 32]. 
5.2 T cell specific antigenicity assay 
Peptides with atypical anchoring residues for a related MHC-I allele always display very 
low binding affinity for MHC-I molecule tested in vitro. However, some of these peptides 
may possess potent antigenicity to induce robust and specific T cell responses. Therefore, it 
is commonly considered that the most definitive means of defining an epitope is to test 
peptide-specific T cell responses. Numerous techniques are currently utilized in peptide 
specific T cell determination, including MHC tetramer staining, enzyme-linked immunospot 
(ELISPOT) assay, intracellular cytokine staining (ICS), cytotoxicity assay (such as lactate 
dehydrogenase release assay and 51Cr release assay) and T-cell proliferation assay [18-33]. 
5.3 Verification of the natural processing of the peptide 
Some artificially synthesized peptides have the potent immunogenicity to trigger specific T 
cell responses and binding affinity to the related MHC molecules in vitro. However, these 
www.intechopen.com
 
Understanding Tuberculosis – Analyzing the Origin of Mycobacterium Tuberculosis Pathogenicity 
 
440 
peptides cannot be generated through natural processing and presenting steps [42]. 
Therefore, demonstrating that a given peptide is processed naturally is a prerequisite to 
epitope identification. There are two conventional techniques by using reversed phase high-
performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) to analyze if a 
peptide is naturally processed. One method is to manipulate the peptide through the 
following procedures: (1) Target cells are transfected with specific MHC-I allele; (2) The cells 
are harvested, and the MHC molecules expressed on the surface of the cells are purified; (3) 
The peptides bound to the MHC molecules are acid-eluted, purified and finally analyzed by 
MS [43]. The other technique is to cleave the longer peptides which include the potential 
epitopes with purified proteasome complexes in vitro. Then, production of peptides by the 
digestion is analyzed by RP-HPLC and MS [44]. However, the results of this method must 
be analyzed carefully, because proteasome digestion can only generate the proper C 
terminus of the MHC-loaded peptides [11]. 
6. Development of CD8
+
 T cell epitope-based vaccines 
One of the approaches to find effective and safe vaccines is epitope-based DNA vaccination 
that enables focusing of the immune response on important and highly conserved epitopes 
[45]. This provides the opportunity to use specific epitopes to shift the immune system 
toward a Th1 or a Th2-mediated immune response and eliminate the unwanted responses. 
Besides that, CTL epitope-based immunization has the advantage of eliciting immune 
response only against the protective epitope and avoidance of epitope drift in Mycobacterium 
tuberculosis infection [46]. 
In many cases, a single CTL epitope-based DNA vaccine could not be fully protective 
against the Mtb infection. Development of epitope-based vaccines has been hampered for its 
relatively low antigenicity. Thus, different vaccine patterns and delivery methodologies 
have been developed, which include synthetic multivalent peptide vaccine, recombinant 
protein vaccine, DNA vaccine, viral vector, protein carrier, and adjuvant, to solve the 
problem. Studies of Mtb in human indicate that the induction of broad T-cell mediated 
immunity to Mtb and Type 1 cytokines including interleukin-2 (IL-2), interferon-γ (IFN-γ), 
and tumor necrosis factor α (TNF-α) are essential for Mtb vaccine design [47]. Vaccines 
based on CTL epitopes represent a logical approach to generate effective cellular immunity 
in both the prophylactic and therapeutic settings because multiple epitopes can be 
incorporated into the vaccine design with the goal of inducing broadly reactive responses 
composed of multiple CTL clones directed against different epitopes. DNA vaccines derived 
from multiple epitopes have been reported to induce broad CTL responses against HIV, 
HBV, and SARS-CoV [48-50]. Although epitope-based vaccines are often thought to be 
limited with respect to HLA polymorphism and population coverage, the use of supertype-
restricted epitopes, those capable of binding with significant affinity to multiple related 
HLA alleles, provides a means to address this problem [51]. There are several problems 
which need to be solved in the future studies of epitope-based Mtb vaccines, such as the 
safety of the DNA vaccine, the development of better adjuvants, the difference and mutation 
among the Mtb strains, complete clearance of the Mtb, the results from challenge models in 
rats or guinea pigs inconsistent with that of clinical trials.  
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